Title |
Galanin – 25 years with a multitalented neuropeptide
|
---|---|
Published in |
Cellular and Molecular Life Sciences, May 2008
|
DOI | 10.1007/s00018-008-8153-8 |
Pubmed ID | |
Authors |
K. Mitsukawa, X. Lu, T. Bartfai |
Abstract |
Galanin, a neuropeptide widely expressed in the central and peripheral nervous systems and in the endocrine system, has been shown to regulate numerous physiological and pathological processes through interactions with three G-protein-coupled receptors, GalR1 through GalR3. Over the past decade, some of the receptor subtype-specific effects have been elucidated through pharmacological studies using subtype selective ligands, as well as through molecular approaches involving knockout animals. In the present review, we summarize the current data which constitute the basis of targeting GalR1, GalR2 and GalR3 for the treatment of various human diseases and pathological conditions, including seizure, Alzheimer's disease, mood disorders, anxiety, alcohol intake in addiction, metabolic diseases, pain and solid tumors. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 1% |
United Kingdom | 1 | 1% |
Spain | 1 | 1% |
United States | 1 | 1% |
Unknown | 70 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 20 | 27% |
Researcher | 16 | 22% |
Student > Bachelor | 12 | 16% |
Student > Master | 5 | 7% |
Professor | 2 | 3% |
Other | 7 | 9% |
Unknown | 12 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 22 | 30% |
Medicine and Dentistry | 12 | 16% |
Neuroscience | 6 | 8% |
Psychology | 6 | 8% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Other | 7 | 9% |
Unknown | 17 | 23% |